Drug intelligence / Profile preview

BACE2 siRNA

Development stage
Preclinical
Lead developer
Mayo Clinic
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

BACE2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the beta-site amyloid precursor protein-cleaving enzyme 2 (BACE2). BACE2 is a protease that, under physiological conditions, typically acts as an alpha-secretase, cleaving the amyloid precursor protein (APP) within the amyloid-beta (Aβ) sequence to prevent the formation of toxic Aβ plaques. In research contexts, such as studies involving human brain microvascular endothelial cells (BMECs), BACE2 siRNA is utilized to investigate the enzyme's role in APP metabolism and its potential involvement in Alzheimer's disease pathogenesis. Experimental results indicate that knockdown of BACE2 reduces the secretion of the neurotrophic product soluble APP alpha (sAPPα) and may influence the expression of other proteins like BACE1 and ADAM10, suggesting that BACE2 inhibition could impair protective pathways in the brain.

Other names
BACE2siRNABACE-2siRNABACE 2siRNABACE2 small interfering RNABACE-2 small interfering RNABACE 2 small interfering RNA
02

Targets

Innate immune RNA sensorsBACE2 (Beta-site amyloid precursor protein cleaving enzyme 2)

Beyond the preview

Go deeper on BACE2 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BACE2 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call